I just bought this pharma stock for its next generation of blockbuster drugs — and its dividend

CNBC - Oct 27, 2026

AbbVie is entering a new chapter of growth, fueled by its blockbuster immunology drugs and expanding neuroscience business. Investor Kevin Simpson shares why he's optimistic.

Read full article

More News

Expert Features

The Expert Features reports on the issues and the world’s everyday news. Handled by experts in different niches, you will find different subjects and perspectives.